At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...

CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial ...

we used a temporary price dislocation caused by disappointing clinical trial results to purchase shares of Novo Nordisk A/S (NYSE:NVO), a Danish-based leader in diabetes and obesity treatments.

The glucagon-like peptide-1 (GLP-1) analogue is already a big earner for Novo Nordisk in a lower 1.8g formulation - Victoza - that is used to treat type 2 diabetes and achieved sales of 9.4 ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the ... the same active ingredient as its popular obesity treatment, Wegovy. With the FDA's approval, the ...

GLP-1 drugs are being studied in a growing number of indications, and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with ... "From my point of view as a doctor, you don't get [diabetes, obesity, chronic kidney disease and ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...

Novo Nordisk's phase 3 CagriSema study on obesity, named "REDEFINE-1." Defendants' statements failed to disclose or otherwise misled investors as to the nature of the dosages provided to patients ...